Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Things could get UGLY..http://www.cdc.gov/swineflu/
Telik's product development focus is on cancer. We currently have two candidates in clinical development:
TELCYTA® (Canfosfamide HCl)
A cancer cell-activated small molecule in development for ovarian and non-small cell lung cancer. Learn more about TELCYTA®
TELINTRA® (Ezatiostat HCl)
A small molecule bone marrow stimulant, is in a Phase 2 trial in myelodysplastic syndrome. Learn more about TELINTRA®
Preclinical Pipeline
Additional potential product candidates in our pipeline have resulted from our ongoing discovery research programs and our collaborations with leading cancer centers. These include inhibitors of enzymes we believe are critical to the growth of cancer cells, and MCP-1 inhibitors that have potential for the treatment of cancer and inflammatory diseases. View preclinical pipeline
TOP INSTITUTIONAL HOLDERS
Holder Shares % Out Value* Reported
MORGAN STANLEY 3,204,738 6.01 $1,217,800 31-Dec-08
EASTBOURNE CAPITAL MANAGEMENT LLC 12,522,075 23.50 $4,758,388 31-Dec-08
Barclays Global Investors UK Holdings Ltd 1,376,149 2.58 $522,936 31-Dec-08
RENAISSANCE TECHNOLOGIES, LLC 1,224,200 2.30 $465,196 31-Dec-08
OPPENHEIMER FUNDS, INC. 10,617,765 19.92 $4,034,750 31-Dec-08
DIMENSIONAL FUND ADVISORS INC 569,851 1.07 $216,543 31-Dec-08
SHAW D.E. & CO., INC. 513,733 .96 $195,218 31-Dec-08
VANGUARD GROUP, INC. (THE) 467,142 .88 $177,513 31-Dec-08
GMT CAPITAL CORP 259,100 .49 $98,458 31-Dec-08
NORTHERN TRUST CORPORATION 136,392 .26 $51,828 31-Dec-08
By KATHLEEN MADIGAN
Private-sector jobs in the U.S. fell a steep 742,000 in March, according to a national employment report published Wednesday by payroll giant Automatic Data Processing Inc. and consultancy Macroeconomic Advisers.
That's much higher than the 656,000 loss forecast by economists in a Dow Jones Newswires survey.
MORE
Real Time Econ: What's Keeping You Up?
Real Time Econ: Manufacturing Recovery Some Time Off
Euro-Zone Unemployment Hits 8.5%
Laid Off: Age Matters in Job Hunt
Separately, U.S. construction spending fell a fifth month in a row during February, but the drop was much smaller than expected, with surprising resilience in the commercial and public sectors. Meanwhile, the Institute for Supply Management's March manufacturing index rose a bit to 36.3 compared to 35.8 last month. The result was better than expected, but still indicates contraction in the industry.
The ADP survey tallies only private-sector jobs while the Bureau of Labor Statistics' nonfarm payroll data, to be released Friday, include government workers. Economists surveyed by Dow Jones Newswires expect that the BLS will report job losses totaling 673,000 for March.
That is on top of the 651,000 nonfarm jobs lost in February and the 4.4 million lost since the recession began.
"Despite some recent indications that stock prices, consumer spending, and housing activity may be bottoming out, employment, which usually trails overall economic activity, is likely to remain very weak for at least several more months," said Joel Prakken, chairman of Macroeconomic Advisers.
The new ADP report showed large businesses with 500 employees or more shed 128,000jobs and medium-sized businesses lost 330,000jobs last month. Small businesses that employ fewer than 50 workers cut 284,000 jobs.
Service sector jobs fell 415,000 in March, while manufacturing employment dropped 206,000.
ADP, of Roseland, N.J., claims to process the payment of one in six U.S. workers, while Macroeconomic Advisers, based in St. Louis, is an economic consulting firm.
In another job report, TrimTabs Investment Research said it estimated that the U.S. economy lost between 700,000 and 750,000jobs in March. TrimTabs uses daily income tax withholdings into the U.S. Treasury to estimate changes in employment.
"Investors who think the economy is bottoming out are going to get quite a shock this spring," said Charles Biderman, chief executive of TrimTabs.
But outplacement firm Challenger Gray & Christmas said that major U.S. companies announced 150,411 job reductions in March. That was the second monthly decline.
Manufacturing Continues to Contract
The recession continued to weigh heavily on U.S. factories last month, sending manufacturing activity down for the 14th straight month.
Private research group the Institute for Supply Management reported Wednesday that its March manufacturing index stood at 36.3 from 35.8 the month before. March's reading was above the 35.0 reading expected by economists, although it remained well inside contractionary territory. Readings under 50 indicate contraction.
"The rapid decline in manufacturing appears to have moderated somewhat, as the PMI remains in the mid-30s for a third consecutive month," said Norbert Ore, who directs the survey.
The ISM had little positive to report about the state of factories in March, with the production index at 36.4, from 36.3 in February.
The new orders index came in at 41.2, from 33.1. This was the first time this index was above 40 in seven months.
Hiring had yet another bad month at a reading of 28.1, from 26.1. Inventories continued to shrink, coming in at 32.2, versus the prior month's 37.0.
Meanwhile, inflation pressures continued to retreat, albeit at a less rapid pace, with the prices index at 31.0. It was 29.0 in February.
Construction Spending Falls Again
Total construction spending decreased by 0.9% at a seasonally adjusted annual rate of $967.52 billion compared to the prior month, the Commerce Department said Wednesday. Spending fell 3.5% in January; originally, January spending was seen 3.3% lower.
Wall Street had expected February construction spending would fall by 2.0%. The last time spending climbed was September; it's down 10% year over year. Recent government data showed the construction industry lost 104,000 jobs in February, with employment dropping by 1.1 million since peaking in January 2007. "Employment fell sharply in both the residential and non-residential components of the industry in February," the Labor Department payroll employment report issued March 6 said.
Residential construction spending plunged in February, Wednesday's report said, dropping by 4.1% to $282.6 billion. Residential spending decreased 3.5% in January; it was originally seen 2.8% lower for the month. Year over year, residential spending was 29.2% below the February 2008 level.
Finding a Bottom for Home Prices
4:43
David Berson, chief economist of PMI Group, talks to MarketWatch's Stacey Delo about how the housing market will rebound before jobs do, and why he expects home prices to bottom for most of the U.S. in early 2010. (April 1)
Other data indicated strength in the U.S. housing sector during February, with builders breaking ground at an increased rate and sales of new homes rising for the first time in seven months. Housing starts rose 22.2% and sales of single-family homes climbed by 4.7% in February. But, in a reminder the sector is still in a slump, the S&P/Case-Shiller home-price indexes Tuesday showed 14 of 20 major metropolitan areas posted price declines of more than 10% from a year earlier.
And while housing starts surged in February, groundbreakings were 47.3% below the pace of construction a year earlier, in February 2008. Along with weakness in housing is softness in commercial construction. The data Wednesday showed non-residential construction spending making a surprising climb, up 0.5% in February. Outlays rose for office buildings and hospitals, while falling for roads and water supply facilities. Yet year over year, commercial construction has increased a mere 1.3%. Fewer new homes suggest fewer new neighborhoods. Tight credit conditions are restraining commercial construction. The recession has pushed vacancy rates up and lease rates down. The Federal Reserve's latest "Beige Book" report on the economy said demand fell further early this year for commercial, industrial, and retail space. With construction slowing across the U.S., the Beige Book cited "assorted reports (that) suggest that market participants expect this weakness to continue at least through the end of 2009."
Wednesday's Commerce data said construction spending in the private sector during February decreased by 1.6% to $665.9 billion. Spending fell 4.0% in January.
Public-sector construction spending increased 0.8% to $301.7 billion. January outlays fell 2.4%. Federal government construction outlays rose 0.8%, as, surprisingly, did state and local spending, which is much larger than federal spending, in dollars. Tax revenues to governments are flowing less freely amid the recession. Corporate profits after taxes tumbled 28% in October through December from the third quarter, a Commerce Department report issued last week said. And because their assets -- homes and stock market accounts -- have eroded, people possess less value for governments to tax.
—Michael S. Derby and Jeff Bater contributed to this article.
Write to Kathleen Madigan at kathleen.madigan@dowjones.com
MORE IN CAREERS MAIN
EmailPrinter FriendlyOrder Reprints
Share:
CURRY POWDER:
Introduction
It is reported that India has very low, almost non-existent Alzheimers disease. The research is strong, and people are discussing it across the world's oceans.
Give your tires BITE
In mud, sand, SNOW and ICE!
Carry Lions Grip
TRACTION PADS™
MAIN MENU
Introduction
What Curry Is
Curcumin
Turmeric
Senior Slowdown
Starting Out
Cooking Curries
Toiletries
Effects & Benefits
History of Curry
In India
Scientific Research
Ingredients
Online Articles
Posts
Buy Online
Restaurants
Links
National Agric. Library
FDA
Related Directories
Search Newsgroups
Foods Composition
Look Up
Scientific Articles
By Topic CoughWontStop
Adelle Davis Revisited
TJOG Salad Diet
New Web Surfer?
<
Trouble?
Get your Car or Truck...UNSTUCK!
With Lions Grip
Traction Pads tm
curry powder curry powder curry powder curry powder curry powder curry powder In April, 2002, this website's author learned of the claim that there is no Alzheimer's disease in India. Since her family is afflicted with Alzheimer's, and she herself had her share of "senior slowdown," this news was of immense interest. A simple Internet search found the claim touted by such substantial sources as the Leather Research Institute in India, and Discover.com, as well as several health-oriented online sources. Discussions with many Indians uncovered a general and near-total absence of knowledge of Alzheimer's Disease, due to the fact that it does not occur among them at all. Two Indian pharmacists, however, both attest that there is "practically no" AD in India.
Nowhere, however, have we yet found any reference to a large survey on Alzheimer's in India. The claim of "no AD" is already being denied by a group of doctors in India, at a website called AlzheimersIndia.com. They have emailed this author that the rate of Alzheimers in India is the same as the rest of the world: about 4 to 5% of people over age 65. This website is being put up with the intention of finding the source of the "no Alzheimers" claim, and examining it for its benefits or drawbacks. (Please use the "Contact Us" box to the left if you can assist.)
Along with the news of non-existent Alzheimers in India, the report came that a substance called Curcumin (an extract of turmeric which is a major ingredient in curry powder) is being credited with extremely beneficial effects on health problems of all kinds: hiv, cancer, diabetes, healing of muscle injuries, and myriad other maladies. The research on Curcumin is quite full and convincing. (See the Research page for a list of some of the studies on Curcumin.)
Upon hearing this news, and remembering some of the remarkable health and cognitive abilities of Indian friends she had known in Asia, the author right away began adding curry powder, in small amounts, to every meal. She sprinkled it on food, both in cooking and at the table, approximately as much as one would use of salt, perhaps a bit more. She fortunately had some curry powder from an Indian food store on hand. In a very short time, two or three days, she noticed very great improvement in many aspects of her "senior slowdown." (Discussed more fully in the Effects and the Senior Slowdown pages.) Memory, word recall, handwriting (which had become shaky), and rather large need for sleep, all improved greatly in this near-instantaneous time. Most importantly, the ability to keep several things in mind returned to mid-adult level. This dramatic experience has fuelled the fire to build this website.
Talking to Indian friends, the author often gets the response, "I've used curry powder and these spices all my life, and I've never noticed anything like this." This is followed by a significant pause, and a smile, as both share the realization of why this is so. And therefore, why this discovery may be so vitally important in the rest of the world.
Curry powder is largely composed of turmeric. Turmeric is the source of Curcumin, among many other compounds. The other spices and herbs in curry powder, almost every one, are known from early times for improving mental functioning ("for getting rid of vapours in the braynes"). Curry powder offers a pleasant, easy way to add these vitally important substances to one's diet. A good teaspoon of curry powder (yes, the kind in the supermarket) per pound of meat and/or vegetables in any recipe will make that dish into a mild "curry". Use less to enhance the natural flavors of your dishes without dominating them. Best is to simply keep curry powder at the table and sprinkle it lightly onto your food --- it is already roasted, and blends well with many savory dishes such as soups, omelettes, meats, vegetables, rice, pasta, etc.
If tried on every meal for just a few days, a new clarity of mind may well be noticed, subtle but undeniable. Several different details can be held in mind. Sequences of all kinds can be remembered. The elusive word turns up easily. The handwriting clears up. Fine motor skills such as threading a needle or attaching a piece of jewelry return. Balance may return. The desire to organize and clean returns. Enthusiasm for one's life may become the dominant emotion. More at the Starting Out page.
Watch out for these:
Some unpleasantness may be noticed if one suffers from advanced gall bladder trouble, since curry powder stimulates the gall bladder. Also, if one uses too much right at the table, it might upset the stomach. Sprinkle it on more than salt, but less than salsa. Regular salt shakers don't let the curry powder pass through. Use shakers with large holes, like parmesan cheese shakers available at Smart and Final.
Join us in discussing and sharing the Curry Powder discoveries and information as we find out more. Join the free email group, "Curry_Powder" at Yahoo!Groups
There are two steps to joining:
1. Join Yahoo!Groups (a simple process, no cost). Click Here if you're not yet enrolled in the Yahoo!Groups system and wish to "Register", as they call it. (This step takes you to Yahoo!Groups Home Page; it does not commit you to anything.)
2. Join the Curry_Powder group within Yahoo!Groups. Click here to join the Curry_Powder group, only if you've already enrolled in the Yahoo!Groups system. (This step also does not commit you to anything; it takes you to the Curry_Powder group's Subscribe form.)
Yahoo!Groups (formerly eGroups, formerly Onelist) is unique in the world of discussion groups. YahooGroups has far more than 1,000,000 groups, with well over 10,000,000 members, and is gaining over 1,000 new groups a day. Why there are no press articles about it is quite a mystery. The author learned about it through a group called "Truckers' Wives"!
Our Curry Powder group at Yahoo!Groups is the only discussion group of its kind, devoted to using curry powder for health. It's totally free, no charge, and you don't need to reveal any personal information. As the Curry Powder group grows, imagine being able to ask several other people instantly, in just one email, whatever is concerning you about health, curry powder, or anything even slightly related to these ideas. Get instant information as members discover and post it to the group.
Hope to see you there!
March 12, 2009 - 4:05 PM EDT
APPY 1.90 0.30
Today 5d 1m 3m 1y 5y 10y
AspenBio Pharma to Proceed With FDA 510(k) Application for AppyScore(TM)
Management to Host Conference Call Today at 4:30 ET
CASTLE ROCK, CO -- (Marketwire) -- 03/12/09 -- AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, today reported additional information and planned next steps for advancing its AppyScore(TM) product through the Food and Drug Administration ("FDA") application and clearance process following the recently completed pivotal clinical trial. AppyScore(TM) is the world's first blood-based test being developed as an aid in the diagnosis of human appendicitis. Based upon the assessment to date, the following key points are made:
-- The company confirms its plan to file a 510(k) with the FDA to seek
clearance of the AppyScore ELISA product used in the pivotal trial as soon
as the extensive filing application can be completed and reviewed by the
Company's regulatory advisors.
-- AspenBio expects that the product indication will be as an, "Aid in
the Diagnosis of Appendicitis," to be used in conjunction with other
physical and laboratory tests.
-- The clinical trial data analysis supports that the AppyScore analyte
MRP8/14, provides valuable clinical information in the diagnosis of
patients with lower right quadrant abdominal pain.
-- AspenBio believes that the AppyScore test, upon commercialization,
will have a sensitivity and negative predictive value of greater than 90%.
-- Data from the pivotal trial also demonstrated that when the AppyScore
is interpreted in combination with other commonly used indicators, such as
white blood count (WBC), the sensitivity and negative predictive value will
be higher.
In order to analyze the trial data and best determine the appropriate next steps the Company has engaged the assistance of an additional highly experienced FDA consulting group, Becker & Associates Consulting, Inc. Becker & Associates has extensive expertise in medical devices, including in vitro diagnostic devices. The Becker team's lead consultant working with AspenBio is a 24 year veteran of the FDA, including serving as Deputy Director for Science and Regulatory Policy in FDA's Center for Devices and Radiological Health's Office of Device Evaluation (ODE).
The preliminary data as disclosed on January 20, 2009 has been further studied and the findings of the study can now be clarified. This pivotal study included an unexpected number of patients who presented with mild appendicitis when compared to peer reviewed published literature statistics. This was especially prevalent at one of the hospital sites which enrolled the largest number of patients in the study. While these factors reduced the sensitivity of the test in this study population (as one might expect for a marker related to disease progression), it has been concluded that the trial results are statistically valid and supportable and favorably demonstrate the linear relationship between the AppyScore level and pathologically proven appendicitis in patients with acute abdominal pain.
Daryl Faulkner, executive chairman of AspenBio, noted: "In making this decision to proceed we have analyzed an extensive amount of data from numerous perspectives over the past weeks and retested several key elements of the product and its performance aspects and remain convinced that AppyScore, in conjunction with other standard diagnostic approaches, can and will provide the physician with an important new tool to aid in the diagnosis of appendicitis. While the path to file the AppyScore 510(k) with the FDA for clearance has been determined, there can be no assurance that such clearance will be obtained nor the timeline. Additionally, prior to such clearance, the FDA may request additional information and / or clarification of data. The company, in consultation with its FDA advisors, believes that the 510(k) application may be determined by the FDA to be a de novo product submission allowing the application to proceed even if a predicate device is not available. If this happens, we believe there may be benefits to this determination, which could include future flexibility to introduce product upgrades."
The company's commercialization plan to maximize the value and effectiveness of the AppyScore product is to advance the FDA 510(k) clearance process based upon the recent trial data and simultaneously complete development and testing of the rapid assay with reader instrument. This reader instrument is in late prototype development and has many features and benefits over the current ELISA test. Such benefits include rapid results in 15 minutes or less, a fully integrated stand alone assay system that significantly reduces operator dependence and a design to interface with the hospital's LIS system. We are presently estimating that clinical trials of this rapid assay with reader instrument device will commence as soon as development is complete. These trials will be designed to support the 510(k) application for this platform, as well as to provide physicians with additional information on the utility of this product.
AspenBio Patent Issuance
AspenBio also announced that on March 10, 2009, the United States Patent and Trademark Office issued AspenBio's patent directed to methods relating to its appendicitis diagnostic technology. This patent, No. 7,501,256, is entitled 'Methods and Devices for Diagnosis of Appendicitis.'
Conference Call
The company will hold a conference call today at 4:30 PM Eastern Time to discuss these developments and related plans. AspenBio management will host the presentation, followed by a question and answer period. Please call the conference telephone number 5-10 minutes prior to the start time:
U.S./Canada: 800-895-0231
International: 785-424-1054
Conference ID: 7ASPENBIO
An operator will register your name and organization and ask you to wait until the call begins. If you have any difficulty connecting with the conference call, please contact the Liolios Group at 949-574-3860.
An audio replay of the call will be available for seven days following the call:
U.S./Canada: 800-723-0479
International: 402-220-2650
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture and marketing of novel proprietary products. The company continues to advance development and testing of its blood-based human diagnostic tests designed as an aid in the diagnosis of human appendicitis. AspenBio Pharma was originally formed to produce purified proteins for diagnostic applications and has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. For more information, go to http://www.aspenbiopharma.com.
Forward-Looking Statements
This news release includes "forward-looking statements" of AspenBio Pharma, Inc. ("APPY") as defined by the Securities and Exchange Commission (the "SEC"). All statements, other than statements of historical fact, included in the press release that address activities, events or developments that APPY believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors APPY believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of APPY. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including statements regarding the ability to successfully complete the clinical trial data assessments required for FDA submission, obtain FDA approval for, cost effectively manufacture and generate revenues from the appendicitis test as well as the animal products and other new products, execute agreements required to successfully advance the company's objectives, retain the scientific management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, fluctuations in sales volumes, obtain and enforce intellectual property rights, and realization of intangible assets. Furthermore, APPY does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this news release should be considered in conjunction with the warnings and cautionary statements contained in APPY's recent filings with the SEC.
For more information contact:
AspenBio Pharma, Inc.
Gregory Pusey
Vice Chairman
Tel 303-722-4008
Investor Relations:
Liolios Group, Inc.
Scott Liolios or Ron Both
Tel 949-574-3860
Source: Marketwire (March 12, 2009 - 4:05 PM EDT)
News by QuoteMedia
todd h, Bragg vinegar can be found in many health food stores.http://www.bragg.com/books/acv_excerpt.html
STEVIA is the answer..
ArticlePhoto (1)Comments (11)
The Zero-Calorie Sweetener Stevia Arrives
It soon could be added to foods from yogurt to diet soda
By Adam Voiland
Posted July 28, 2008
Updated on 08/29/08: An earlier version of this story did not reflect a recent announcement of a new line of beverages by PepsiCo and Whole Earth Sweetener. This version also explains in greater detail the regulatory process as it applies to stevia.
There's a new sugar substitute on the market with a really sweet pitch: zero calories, zero carbohydrates, and zero chance of a spike in blood sugar levels.
Several companies are just out with new products derived from the leaves of the Latin American herb stevia, which contain a substance hundreds of times more potent than sugar. Arizona-based Wisdom Natural Brands was the first to start aggressively marketing packets of its powdered SweetLeaf earlier this summer. Agribusiness giant Cargill, working in collaboration with Coca-Cola, followed with Truvia. And PepsiCo, with Whole Earth Sweetener Co., has developed a new line of beverages sweetened with a stevia product called PureVia. "Soon you'll see stevia in pretty much every food product you can imagine," predicts Oscar Rodes, the founder of Texas-based producer Stevita Co., who is betting the herb could eventually account for 20 percent of the overall sweetener market.
Related News
A Sampling of Stevia Products
Why One Doctor Says 'No' to Screening Tests
11 Olympians and Their Favorite Workouts
Discuss Diet And Nutrition
Stevia's already a hit with fans of alternative medicine, since it has long been sold by health food stores as a dietary supplement. (The Food and Drug Administration hasn't yet endorsed the safety of the new products as food additives, but the companies claim they've met requirements to establish stevia as "generally recognized as safe" by scientists.) Boosters tout all those zeros as evidence that the herb is far more healthful than sugar and artificial sweeteners. A packet of sugar has about 11 calories, 3 grams of carbohydrates, and an estimated "glycemic load" of 2, for example. Dietitians recommend keeping your glycemic load, a measure of how much particular foods raise blood sugar levels, below about 100 a day. A packet of sucralose (Splenda) has 3 calories, 1 gram of carbohydrates, and a glycemic load of 1, according to NutritionData.
Indeed, some research suggests that stevia may improve health. Jan Geuns, a biologist in Belgium who has organized symposiums to explore the substance's pharmacological effects on humans, points to two Chinese studies that have found it can significantly lower blood pressure among people with mild hypertension. Danish researchers have reported that stevia seems to reduce blood glucose levels among patients with type 2 diabetes. But the effects were seen only at doses far greater than those for stevia used as a sweetener, Geuns cautions, so the typical user would experience little effect.
The dietary supplements have been slow to catch on with mainstream consumers, partly because of a bitter licorice aftertaste. Makers of the new sweeteners claim to have found ways around that; since the degrees of processing and purity vary significantly—some products contain added flavors, bulking agents, or fiber—consumers may want to try several brands. For the best taste, Rodes recommends using products that are at least 95 percent pure; Geuns says to look for products rich in a substance called rebaudioside A.
It's not just taste that has hampered consumer acceptance; the herb's been trapped in a regulatory limbo. Since the '60s, a trickle of animal studies has suggested that stevia might cause potentially cancerous mutations or reproductive problems. Though the studies' methodologies were criticized and stevia had a good safety record in countries where it was widely used at the time, such as Japan, regulators imposed an import ban in 1991. The stevia industry howled, charging that artificial-sweetener makers just wanted to clear the market of competition.
Rigorous research. In 1994, a new law that revamped the way foods are regulated led to a lift of the import ban and put stevia in the odd position of being considered safe if marketed as a dietary supplement but not if used in foods or drinks. "It's a completely absurd and confusing situation for consumers," says James Turner, a partner at Swankin & Turner, a consumer rights law firm based in Washington, D.C., who has expertise on the regulation of sweeteners. The intent, according to the FDA, is to prove stevia safe through rigorous research before people start widely consuming it in food.
In the case of Truvia, the research has been done, says Ann Tucker, a spokesperson for Cargill. In May, the company notified the FDA that a series of studies had affirmed Truvia's safety. "We did an absolutely thorough job," says Tucker, "and published the results in peer-reviewed scientific journals." She cautions that the findings apply only to Cargill's rebaudioside A extract. In June, Wisdom Natural Brands announced that two independent expert panels that reviewed the safety of SweetLeaf gave it a thumbs up.
1 2 Next Page >
Tags: FDA | food | products | sugar
Print | Subscribe | + Share this Story | Yahoo! Buzz | Sphere: Related Content
Reader Comments
Read all 11 comments about this article
stevia
hello , i would like a address so i can send in a money order to order 100 pac. in a box . please leet me know
thanks
bertha
i can only come here to the library to use this computer. i will be here monday
bertha of NM
Dec 05, 2008 14:21:17 PM [permalink] [report comment]
stevia
hello , i would like a address so i can send in a money order to order 100 pac. in a box . please leet me know
thanks
bertha
i can only come here to the library to use this computer. i will be here monday
bertha of NM
Dec 05, 2008 14:21:10 PM [permalink] [report comment]
Truvia and PureVia -- Neither True nor Pure
Truvia's first sweetener ingredient is Erythritol -- a sugar alcohol that can cause stomach upset. PureVia relies on both Erythritol and Isomaltulose. These are not true Stevia based sweeteners.
The best. truly stevia based sweetener on the market is a new one called Stevia Extract In The Raw -- made by the people who make Sugar In The Raw. Not only is it a pure, 100% natural, stevia based sweetener with no calories -- it's also much less expensive than the other two!
Michael Decker of
Nov 11, 2008 09:37:38 AM [permalink] [report comment]
Read all 11 comments about this article
Add your thoughts
Subject:
* Type your comments here: (3000 characters left)
Your name:
* Your E-mail address:
* State: Submit
Your comment will be posted immediately, unless it is spam or contains profanity. For more information, please see our Comments FAQ.
advertisement
PEOPLE WHO READ THIS ALSO READ ...
10 Things the Food Industry Doesn't Want You to Know
Gluten-Free Diet: a Cure for Some, a Fad for Most
9 Great Breakfast Ideas for Kids of All Ages
Findings Challenge Tight Glucose Control for Critically Ill Patients
Meet 11 Olympic Contenders and Their Favorite Workouts
advertisement
HEALTH NEWS FROM HEALTHDAY
Savella Approved for Fibromyalgia
FDA Issues Final Regulations for Genetically Engineered Animals
Family Docs Do Colonoscopies Safely
Sleep Apnea Seems to Wear Down the Brain
Mothers, Newborns at High Risk in Developing World
More Headlines From HealthDay
advertisement
FEATURED VIDEO
Birth Control Methods
Learn about condoms, diaphragms, and other barrier methods of birth control.
Signs of Alzheimer's
Learn the symptoms and risk factors of Alzheimer's disease.
Rheumatoid Arthritis
Rheumatoid arthritis, one of the most severe types of arthritis, affects people of all ages.
What Is Diabetes?
Diabetes, if unchecked, can lead to very serious conditions such as kidney problems, blindness, and amputations.
Prepping for Pregnancy
How to get your body and mind prepared for a safe and healthy pregnancy.
Cholesterol: Good and Bad
Why it's important for you to always know your cholesterol numbers.
HEALTH HEADLINES FROM U.S. NEWS
VitaminWater Health-Claim Lesson: Read Labels
Estrogen Paradox: Can HRT Be Both Good and Bad for the Brain?
SCHIP Bill Passes House: First Step in Expanding Health Insurance for Kids
Health Buzz: Children's Health Bill SCHIP and Other Health News
ADHD Summer Programs Near You
advertisement
Cyclacel Pharmaceuticals, Inc. (CYCC) At 3:59PM ET: 0.51 0.06 (13.33%)
MORE ON CYCC
Quotes
Summary
Real-Time ECNNEW!
Options
Historical Prices
Charts
Interactive
Basic Chart
Basic Tech. Analysis
News & Info
Headlines
Financial Blogs
Company Events
Message Board
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Components
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Major Holders
Insider Transactions
Insider Roster
Financials
Income Statement
Balance Sheet
Cash Flow
Major Holders Get Major Holders for:
BREAKDOWN
% of Shares Held by All Insider and 5% Owners: 4%
% of Shares Held by Institutional & Mutual Fund Owners: 52%
% of Float Held by Institutional & Mutual Fund Owners: 54%
Number of Institutions Holding Shares: 25
MAJOR DIRECT HOLDERS (FORMS 3 & 4)
Holder Shares Reported
MORGAN STANLEY N/A 2-Jan-09
FLYNN JAMES E N/A 19-Nov-08
ROMBOTIS SPIRO GEORGE 441,548 2-Dec-08
MCBARRON PAUL 126,054 18-Nov-08
CHIAO JUDY 48,168 9-Jun-08
ADVERTISEMENT
TOP INSTITUTIONAL HOLDERS
Holder Shares % Out Value* Reported
FEDERATED INVESTORS, INC. 1,275,467 6.24 $1,530,560 30-Sep-08
Invesco Ltd. 931,313 4.56 $1,117,575 30-Sep-08
Argenis Capital Advisors LLC 646,000 3.16 $1,233,860 30-Jun-08
DIMENSIONAL FUND ADVISORS INC 586,665 2.87 $703,998 30-Sep-08
STARK OFFSHORE MANAGEMENT, LLC 421,429 2.06 $505,714 30-Sep-08
MORGAN STANLEY 2,995,424 14.66 $3,594,508 30-Sep-08
DEERFIELD MANAGEMENT 2,126,578 10.41 $2,551,893 30-Sep-08
PERCEPTIVE ADVISORS LLC 347,512 1.70 $417,014 30-Sep-08
RENAISSANCE TECHNOLOGIES, LLC 303,700 1.49 $364,440 30-Sep-08
FIRST NEW YORK SECURITIES L.L.C. 213,767 1.05 $256,520 30-Sep-08
TOP MUTUAL FUND HOLDERS
Holder Shares % Out Value* Reported
FEDERATED KAUFMANN FUND 1,746,833 8.55 $3,301,514 31-Jul-08
DFA U.S. MICRO CAP PORTFOLIO 196,819 .96 $330,655 31-Aug-08
VANGUARD EXTENDED MARKET INDEX FUND 105,191 .51 $126,229 30-Sep-08
DFA Tax Managed U.S. Targeted Value Port 81,921 .40 $137,627 31-Aug-08
DFA U.S. SMALL CAP SERIES 69,644 .34 $117,001 31-Aug-08
DFA TAX-MANAGED U.S. SMALL CAP PORTFOLIO 61,563 .30 $103,425 31-Aug-08
ISHARES Russell Micro Cap (TM) Index Fund 32,351 .16 $15,851 31-Oct-08
DFA U.S. Targeted Value Series 16,800 .08 $28,224 31-Aug-08
DFA U.S. Core Equity 2 Portfolio 15,929 .08 $26,760 31-Aug-08
DFA U.S. Vector Equity Portfolio 8,946 .04 $15,029 31-Aug-08
View Transactions for Insiders & Institutional Holders
* Value shown is computed using the security's price on the report date given.
Ground flaxseed: Better than whole?
Does ground flaxseed have more health benefits than whole flaxseed?
- No name / No state given
Mayo Clinic dietitian Katherine Zeratsky, R.D., L.D., and colleagues answer select questions from readers.
Answer
Most nutrition experts recommend ground flaxseed because your body is better able to digest it. Whole flaxseed may pass through your intestine undigested, which means you won't get the health benefits of flaxseed.
Flaxseed is high in fiber, omega-3 fatty acids and phytochemicals called lignans. Flaxseed can help reduce total blood cholesterol and LDL ("bad") cholesterol levels — and, as a result, may help reduce the risk of heart disease. Flaxseed oil also contains omega-3 fatty acids, but it doesn't have the beneficial fiber that the seeds have.
You can purchase raw flaxseed in bulk — whole or ground — at many grocery stores and health food stores. Whole seeds can be ground in a coffee grinder and then stored in an airtight container for several months. Refrigerating whole seeds may also extend their freshness.
Although the Institute of Medicine has not set a recommended daily intake for omega-3 fatty acids, it has established adequate intake amounts of between 1.1 and 1.6 grams a day for adults. One tablespoon of ground flaxseed provides 1.6 grams of omega-3 fatty acids. Tips for including flaxseed in your diet:
Add a tablespoon of ground flaxseed to your hot or cold breakfast cereal.
Add a teaspoon of ground flaxseed to mayonnaise or mustard when making a sandwich.
Mix a tablespoon of ground flaxseed into an 8-ounce container of yogurt.
Bake ground flaxseed into cookies, muffins, breads and other baked goods
You can also use flaxseed in place of eggs in muffins, pancakes and cookies. To substitute flaxseed for one large egg in a recipe, use 1 tablespoon ground flaxseed plus 3 tablespoons water. Keep in mind that it will somewhat alter the texture of the finished product, making it slightly "gummy."
MORE ON THIS TOPIC
Cholesterol: The top 5 foods to lower your numbers
Heart disease prevention: 5 strategies keep your heart healthy
RELATED
White whole-wheat bread: Is it good for me?
Lentils: How do I cook with them?
Canned pumpkin: Better than fresh?
Acai berry products: What are the health benefits?
Vegetable juice: As good as whole vegetables?
Vegetarian diet: How to get the best nutrition
Dietary fiber: An essential part of a healthy diet
Whole grains: Hearty options for a healthy diet
High-fiber foods
Healthy-carb recipes
High-fiber recipes
Meatless recipes
ARTICLE TOOLS
Print
E-mail this
Larger type
Reprints and permissions
By Mayo Clinic Staff
Jan. 19, 2008
© 1998-2009 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.com," "EmbodyHealth," "Reliable tools for healthier lives," "Enhance your life," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.
AN01258
About this site Contact us Site help e-Newsletter Site map Reprints and permissions
Advertise with us
Privacy policy updated Jul 1, 2008
Terms and conditions of use policy updated Jun 20, 2008
LEGAL CONDITIONS AND TERMS OF USE APPLICABLE TO ALL USERS OF THIS SITE. ANY USE OF THIS SITE CONSTITUTES YOUR AGREEMENT TO THESE TERMS AND CONDITIONS OF USE.
© 1998-2009 Mayo Foundation for Medical Education and Research. All rights reserved.
MayoClinic.com Bookstore Diseases & ConditionsDrugs & SupplementsTreatment DecisionsHealthy LivingAsk a SpecialistHealth ToolsSlide ShowsVideoBlogs & Podcasts Home RSS ASK A FOOD & NUTRITION SPECIALIST More Information
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.
Mayo Clinic Book of Alternative Medicine
Healthy Living set - Buy 2 books and get 1 free!
Get your free trial issue of Health Letter now!
More titles from MayoClinic.com Bookstore …
Advertising and sponsorship policy
Jan 11, 2009
uts Lower Cholesterol
Pistachios, Walnuts, Pecans, Others Provide Benefits
© Deborah Mitchell
Sep 28, 2008
A recent study was the first to investigate how pistachios lower cholesterol. It is just one of many studies showing how nuts are heart-healthy.
Pistachios appear to help reduce levels of “bad” cholesterol—low-density lipoprotein cholesterol (LDL)—according to the results of a new study published in The American Journal of Clinical Nutrition. The 2008 Pennsylvania State University study focused solely on pistachios.
Since 2003, the Food and Drug Administration (FDA) has allowed food manufacturers to make a qualified health claim that eating a moderate amount of nuts as part of a low-fat diet can be good for your heart. The nuts named by the FDA include almonds, hazelnuts, pecans, pistachios, and walnuts. Peanuts, which are really a legume, are also included.
Pistachios and Cholesterol
This latest study evaluated 28 adults who had elevated LDL cholesterol levels when the study began. First the participants spent two weeks eating a standard American diet high in fat and without pistachios. Then for one month they ate a low-fat diet without pistachios, followed by one month on a healthy diet that included one daily serving of pistachios, and followed by a fourth month eating a similar diet that included two daily servings of pistachios. The participants took two-week breaks between each type of diet. All the food for the diets was supplied by the study.
The researchers found that LDL cholesterol levels declined by 9 percent when the participants ate one daily serving of pistachios and by 12 percent when they had two daily servings. LDL cholesterol levels did not fall when participants ate the low-fat diet alone.
Other Nuts and Cholesterol
Other studies support the claims that nuts can reduce cholesterol levels. A recent hazelnut study found that men with high cholesterol who supplemented a low-fat, low-cholesterol diet for four weeks with hazelnuts (40 grams daily) experienced a 5.2 percent drop in total cholesterol, 3.3 percent decline in LDL cholesterol, and 12.6 percent rise in “good” cholesterol, high-density lipoprotein (HDL).
Pecans also shine. A 2001 study published in The Journal of Nutrition found that adding pecans to the diet reduced LDL cholesterol by 10.4 percent and raised HDL cholesterol by 5.6 percent.
Eating Nuts
Because nuts are high in calories, moderation is key when eating them for health benefits. Experts agree that 1 to 1.5 ounces of nuts daily is enough to reap heart-healthy effects. One good way to add nuts to your diet without adding extra calories is to use them to replace less healthy fats, like those found in meats and dairy products.
Nuts can also be added to salads, blended into smoothies, used as a topping for vegetables and cereal, or consumed as a nut butter (2 tablespoons is a typical serving; look for all-natural, no salt varieties).
Although many nuts can help lower cholesterol, a few are very high in fat and so should be consumed only in moderation and infrequently. They include Brazil nuts, cashews, and macadamia nuts.
Look for dry roasted, unsalted nuts. If possible buy them fresh; otherwise always check the dates on prepackaged nuts.
Resources
Gebauer Sk et al. Effects of pistachios on cardiovascular disease risk factors and potential mechanisms of action: a dose-response study. Am J Clin Nutr 2008 Sep; 88(3): 651-59.
The copyright of the article Nuts Lower Cholesterol in Nutrition is owned by Deborah Mitchell. Permission to republish Nuts Lower Cholesterol in print or online must be granted by the author in writing.
Pistachios
Health Benefits: Almonds
April 14, 2005
Eating almonds has the same effect as the cholesterol-lowering drugs called statins. A one and a half ounce handful of almonds is a leading source of vitamin E and magnesium and offers protein, fiber, potassium, calcium, phosphorus and iron in 246 calories. Also, almonds (and other nuts) contain phytochemicals, which are plant chemicals that may provide powerful protection against heart disease, stroke, and other chronic diseases.
New research gives even more support to the healthy benefits of almonds: almonds may well be a food that helps fight obesity and diabetes.
At the recent 2005 Experimental Biology conference there were several studies regarding the benefits on almonds. Almonds may lower LDL (aka “bad) cholesterol, and they seem to help block the body’s absorption of both fat and carbohydrates. This has numerous implications for diabetes, obesity, and heart disease. The fiber structure of almonds may be the mechanism behind this phenomenon, and this reduces the calories available from the almonds themselves. Almonds may slow the actual absorption of the carbohydrates into the body, which means that they help to create a slower rise in blood sugar levels – and therefore help to keep insulin levels in check.
Almonds also have greater levels of satiety, that is, satisfaction or fullness from food. This may be due to the high fiber content of the almonds, and this greater satiety leads to an overall satisfaction of hunger that can help people to maintain a healthy weight. The studies done at Purdue University showed that adding nearly two servings of almonds to a person’s diet did not cause them to gain weight or body fat at all, but rather led them to decrease their intake of calories from other sources of food. Therefore they did not consume more calories overall but kept the same levels of consumption despite adding almonds to their diet.
December 10, 2008 - 8:30 AM EST
NUVO 0.305 0.00
Today 5d 1m 3m 1y 5y 10y
Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
SAN CARLOS, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced positive results from the Phase 1 trial of recombinant, secreted protein, NU206, the company's lead compound from its Wnt Therapeutics Program. This single-center, double-blind, placebo-controlled, single-ascending dose (SAD) trial tested the safety, tolerance and pharmacokinetics of a single intravenous (IV) administration of NU206, in 32 healthy male volunteers. Participants were enrolled in four cohorts of varying doses, with a maximum dose of 0.20 mg/kg/day. NU206 had a favorable safety profile, no serious adverse events were observed, and pharmacokinetics were predictable.
'Based on preclinical studies, we believe that NU206 promotes cell growth and repair, and, based also on results from this Phase 1 trial, believe it has the potential to offer a novel approach for the treatment of serious medical conditions such as gastrointestinal (GI) injury, inflammatory bowel disease, and bone disease,' said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. 'Because Nuvelo is in the process of merging with ARCA biopharma to create a cardiovascular-focused company, we are currently evaluating partnership and out-licensing opportunities for NU206 to continue development of the compound.'
About NU206
NU206 (R-spondin1) is a recombinant, secreted protein that acts as a key regulator of the Wnt pathway, the critical pathway that stimulates cell growth and differentiation during homeostasis and pathogenesis in specific tissues including the GI epithelium and bone. Preclinical studies suggest it can promote growth and repair in animal models of radiation or cancer chemotherapy induced GI injury, inflammatory bowel disease, and bone disease.
About Nuvelo and Kyowa Hakko Kirin's Joint Collaborative Effort
Scientists from Nuvelo and Kyowa Hakko Kirin worked together to identify and characterize NU206 as part of a collaboration focused on the discovery of novel, secreted proteins. Nuvelo signed a collaboration agreement with Kyowa Hakko Kirin in April 2005 to develop NU206. Under the agreement, Nuvelo leads worldwide development, manufacturing and commercialization and all operating expenses and profits related to the development and commercialization of NU206 are shared 60% (Nuvelo)/40% (Kyowa Hakko Kirin).
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor which has completed Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and NU206, a Wnt pathway modulator in Phase 1 development for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at its website at http://www.nuvelo.com or by phoning 650-517-8000.
Forward-looking statements
This press release contains 'forward-looking statements' which include, without limitation, statements regarding the completion of the proposed merger transaction between Nuvelo, ARCA biopharma, Inc., or ARCA, and Dawn Acquisition Sub, Inc., the timing, progress and anticipated completion of Nuvelo's clinical stage programs, the potential benefits that patients may experience from the use of our clinical stage compounds, and potential partnership and out-licensing opportunities, which statements are hereby identified as 'forward-looking statements' for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, failure of Nuvelo or ARCA's stockholders to approve the merger, the ability to complete the transaction contemplated by this communication in a timely fashion, uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in the companies' clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's quarterly report on Form 10-Q for the quarter ended September 30, 2008 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.
Additional Information and Where to Find It
Nuvelo has filed a registration statement on Form S-4, and a related proxy statem
SumTingWong AKS NYSE
This is the reason..http://investorshub.advfn.com/boards/read_msg.aspx?message_id=34113174
board # 10933 WU
Pick
ZAGG
ZGEN
PPCO
MTEX
Chartinator,Are you saying that we have seen the low in this market? The USA still has a long and ugly road to travel.
October 27, 2008 - 2:02 PM EDT
EROX 0.30 0.07
Today 5d 1m 3m 1y 5y 10y
Human Pheromone Sciences, Inc. - Shareholder Update
SAN JOSE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- HPSI (OTC Bulletin Board: EROX) releases letter to its shareholders
Dear Shareholders,
In light of events that have shaken the investment community around the
world over the past several weeks, I want to take this opportunity to
update you as to what is happening in your Company at the present time.
Excluding technology advancements, an update of which will be provided
very shortly in another release, the objectives and strategies for the
Company for this year and 2009 are as follows:
-- The Company is continuing to work closely with our current licensees as
they undertake programs to introduce consumer products containing our
patented compounds.
During this year we have continued to be closely involved with the J&J
Personal Products Group as they continue product development efforts
under our License Agreement. This project is ongoing and viable.
In mid 2007, we entered into an agreement with Schwarzkopf and Henkel,
for the inclusion of our patented technology in several of their got2b
brand products sold in the United States. During this year, the
Agreement has been expanded geographically to include Henkel's European
businesses and an additional product line has been included in the
Agreement.
We continue, this year, to work with other U.S. and international
companies including Avon Products, who continue to utilize our
pheromone compounds. In addition, we continue to look
internationally, and continue to enter into agreements with companies
doing business in Mexico and Japan.
In addition, we are in discussions with several other companies in the
United States and overseas, in efforts to open new markets for our
current technology with local companies, with their own infrastructures
here in this country and in foreign markets.
Not only has our Company benefited financially from our agreements with
these world-class companies, our association with them has confirmed
the viability of our technology, an imperative for a small
technology-based business to generate interest of others in the longer
term.
-- While our historical business model has been validated by these
relationships, we are still dependent upon the internal timetable of
these licensees for the generation of revenues for our Company.
However, there are other viable and fast growing channels in which
consumer products are sold, including electronic media, and
direct-to-consumer companies, that may provide a more consistent flow
of revenues to our Company. During this year, your management has been
working to introduce our technology to several companies who are in
leaders in these fields. We hope to be able to provide more specifics
about these efforts shortly.
-- Technology - our heritage, our future; another focus of our Company.
During 2008, we have spent significant amounts of time, but not a lot
of money, in the development of new compounds. You will be hearing
more about the positive results of these efforts in the next two weeks.
-- Merger and Acquisition Opportunities. We feel strongly that our
current technology and new research and development initiatives can
continue to attract world-class partners. We have also undertaken a
program to seek mergers and/or other types of partnerships that can
enhance shareholder value - our ultimate goal.
Unlike many companies whose share price has dropped radically this year,
who have no historic operations, an un-tested business plan and tens of
millions of shares outstanding, our Company has existing relationships and
agreements with worldwide leaders in the consumer products industry, is in
discussions with other international companies for the use of our
technology, looking to expand our relationships to provide a more
consistent stream of revenues, and has a pipeline of additional compounds
that can offer patented differentiation. And, importantly, our cash
assets exceed our current market valuation, and we have no
interest-bearing debt.
Thank you for interest and support. Please do not hesitate to contact me
directly if you have any questions.
Sincerely,
William P. Horgan
Chairman and CEO
408-938-3030
SOURCE Human Pheromone Sciences, Inc.
P
Patriot Coal lowers production estimates
Monday October 6, 8:18 pm ET
Patriot Coal lowers estimate for 3Q production, shares fall sharply
DENVER (AP) -- Patriot Coal Corp.'s shares plummeted Monday amid a broader market decline after the coal mining company said its third-quarter production was expected to be 1.4 million tons less than its initial forecast of 8 million tons.
ADVERTISEMENT
The stock price -- which has lost nearly one-half its value in the past week -- declined amid a market selloff Monday that took the Dow Jones industrials below 10,000 for the first time in four years.
Patriot Coal said Friday it will issue revised financial guidance with its third-quarter earnings release later this month.
It was the fourth Appalachian producer to cut production, and most are blaming labor shortages, increased inspections, permits and geologic conditions, Dahlman Rose & Co. Director Daniel Scott wrote in a client note published Monday.
"Production expectations across all companies have so far decreased 6 million tons since early September and are likely to drop further as all producers in the region, especially (Central Appalachia) are experiencing similar issues," the note stated.
Scott forecast earnings before interest, taxes, depreciation and amortization of $49 million, down from $75 million, and earnings per share at 14 cents, down from 34 cents.
Shares of Patriot Coal dropped $2.36, or 11.6 percent, to $18.05.
Tax on Trades Should Be Part of Rescue Plan, Some Democrats Say
By Laura Litvan
Sept. 25 (Bloomberg) -- A group of House Democrats is proposing to make Wall Street companies and investors pay more of the cost of any financial rescue plan through a new tax.
In a letter sent late yesterday to House Speaker Nancy Pelosi, 16 Democrats asked her to ensure any rescue legislation include a ``transaction tax'' on all U.S. stock trades and on other types of trades, such as credit default swaps, options and futures. They are proposing the tax would be at a rate of one quarter of one percent on all trades.
``The same Wall Street speculators and investors who are principally responsible for having caused this avoidable financial crisis and profited from it must now be required to pay for it, not U.S. taxpayers,'' according to the letter, which was signed by Representative Peter DeFazio, an Oregon Democrat, and Representative Pete Stark, a California Democrat.
In a news conference today, House Speaker Nancy Pelosi said she would support some mechanism that could return more funds to Treasury coffers if the $700 billion to be spent to acquire troubled investments isn't later recouped. She didn't endorse any specific proposal and suggested it is likely to be explored later.
``You might make a judgment down the road that there is a shortfall and it should be covered,'' Pelosi said.
President George W. Bush in a televised address last night urged swift action on the $700 billion rescue plan to help avert ``a long and painful'' recession.
The $700 billion proposal would allow the Treasury to buy troubled assets to restore financial stability, Fed Chairman Ben S. Bernanke said yesterday.
To contact the reporters on this story: Laura Litvan in Washington at llitvan@bloomberg.net; James Rowley in Washington at jarowley@bloomberg.net
CONTEST PICKS UVE ACW
Press Release Source: Aspen Exploration Corporation
Aspen Exploration Announces Two Successful Gas Wells
Monday June 23, 11:25 am ET
DENVER, CO--(MARKET WIRE)--Jun 23, 2008 -- Aspen Exploration Corporation (OTC BB:ASPN.OB - News), with offices in Bakersfield, California and Denver, Colorado, announced that Aspen has completed the drilling of two wells from its 2008 drilling program. The SJDD #11-1 well, located in the Cache Creek Gas Field, Yolo County, California, was drilled to a depth of 4,111 feet and encountered approximately 24 feet of potential gross gas pay in two intervals in the Starkey formation. One of these intervals was perforated and tested gas on a 10/64" choke at a stabilized flow rate of 750 MCFPD and 1380 psig flowing casing pressure. The shut in tubing pressure was 1440 psig and shut in casing pressure was 1500 psig. Aspen has a 30% operated working interest in this well. Gas sales commenced May 20, 2008.
ADVERTISEMENT
The Johnson Unit #13 well, located in the Malton Black Butte Field, Tehama County, California, was drilled to a depth of 4,896 feet and encountered approximately 125 feet of potential gross gas pay in several intervals in the Forbes formation. This well is currently shut in awaiting completion. Aspen has a 31% operated working interest in this well.
Drilling commenced on the Eastby #1-1 well located in the Malton Black Butte Field in Glenn County, California. This well is scheduled to test the Forbes Formation at a total depth of approximately 5,010 feet. Total cost of the well is estimated at $1,000,000; Aspen has a 30.00% operated working interest in this well.
Aspen has entered into an agreement to participate as a non-operated partner in a new exploration program in the Malton-Black Butte Gas Field in Glenn and Tehama Counties, California. This area is east of Aspen's Malton Black Butte project. Several prospects have been identified in this area that will target Eocene, Kione, and Forbes objectives at depths ranging from 1700 to 5800 feet. The first three wells in this project have been completed as gas wells. The fourth well commenced drilling this week, and additional wells are planned in this project for the Fall of 2008. Aspen has a non-operated 7% working interest in the project.
Seismic processing has been completed on Aspen's Strain Ventures 3D-seismic program in Colusa County, California. This 12-square mile survey is adjacent to Aspen's prolific West Grimes Gas Field. Interpretation of this data by Aspen's consultants is in progress and preliminary results have revealed several potential targets. Aspen plans to drill at least two prospects in the West Grimes-Strain Ventures area in the Fall of 2008, contingent upon rig availability and approval of necessary permits. Aspen has a 32% operated working interest in this project.
Aspen currently operates 66 producing gas wells in California and also has an interest in 25 non-operated gas wells.
In 2007 Aspen acquired a 12.5% working interest in the Poplar producing oil field in Roosevelt County, Montana. After 110% payout, Aspen's interest will revert to 10%. Average gross daily production for the months of April and May, 2008, was 287 barrels oil per day. This field also produces a substantial amount of water that is disposed of by injection into a subsurface formation. Aspen believes that ongoing remedial work will increase production over time. Geologists familiar with the Poplar Field believe the Bakken and Nisku Formations, deeper horizons than those currently being produced, have potential in this field.
For more information, contact R. V. Bailey, CEO, in Aspen's Denver office at 303-639-9860. Aspen invites interested parties to visit Aspen's web site at www.aspenexploration.com and be sure to register in the contact box for updated news releases and other information
AFS trinity power corp http://www.afstrinity.com/
Yahoo!My Yahoo!Mail Make Y! your home pageYahoo! SearchSearch:Sign In
New User? Sign UpFinance Home -Help
Home InvestingMarket OverviewMarket StatsStocksMutual FundsETFsBondsOptionsIndustriesCurrencyEducationNews & OpinionMarketsInvesting IdeasExpert AdviceSpecial EditionsCompany FinancesProvidersPersonal FinanceBanking & BudgetingCareer & WorkCollege & EducationFamily & HomeInsuranceLoansReal EstateRetirementTaxesHow-to GuidesGet QuotesFinance Search New! Find Quotes Faster
You no longer need to remember symbols. Simply type in a company name or stock symbol for instant results.
Learn more... Close x 8988914
AP
Zix Expects to Meet Its 4Q Sales Outlook
Tuesday January 8, 11:08 am ET
Zix Expects to Meet Its 4th-Quarter Revenue Outlook on Strong Results From Businesses
DALLAS (AP) -- Zix Corp. said Tuesday it expects to meet its fourth-quarter sales forecast on strong results from its e-mail encryption and e-prescribing operations.
The company previously predicted quarterly revenue between $6.3 million and $6.8 million.
ADVERTISEMENT
Fourth-quarter e-mail encryption orders totaled $6.5 million, leading to a full-year order total of $24.2 million, which is 38 percent higher than the year-ago period. Zix said its PocketScript unit surpassed the high end of its fourth-quarter e-prescribing deployment outlook of 250 to 300 deployments with 327 deployments.
The company estimates 2007 revenue in a range of $23.4 million to $23.9 million, which would be a 28 percent to 30 percent increase from the prior year's results.
Zix also extended a distribution deal with Postini Inc. to package its e-mail encryption service with Postini services and offer them to the Google Inc. unit's customer base.
Shares of Zix gained 28 cents, or 7.5 percent, to $4 in morning trading. The stock has traded in a range of $1.16 to $6.24 over the past year.
Press Release Source: Zix Corporation
Zix Corporation Supports Introduction of Kerry, Ensign e-Prescribing Bill
Thursday December 6, 1:00 pm ET
Medicare Electronic Medication and Safety Protection Act of 2007 ('E-MEDS') Establishes Incentives for Early Adoption of e-Prescribing, Followed by a Requirement to Use e-Prescribing for Medicare Prescriptions by 2011
DALLAS, Dec. 6, 2007 (PRIME NEWSWIRE) -- Zix Corporation (ZixCorp(r)) (NasdaqGM:ZIXI - News), the leader in hosted services for email encryption and e-prescribing, today issued a statement supporting yesterday's introduction of a bi-partisan bill sponsored by Senators John Kerry, John Ensign, Debbie Stabenow, and Mel Martinez in the Senate, and Representatives Allyson Schwartz and Jon Porter in the House to expedite the adoption of electronic prescribing technology in every doctor's office in America.
ADVERTISEMENT
In conjunction with the introduction of yesterday's bill, Former Speaker of the House Newt Gingrich, Senator John Kerry (D-MA), Senator Debbie Stabenow (D-MI), Senator John Ensign (R-NV), Senator John Sununu (R-NH) and Andrew S. Warner, M.D. of Lahey Clinic and Board Member, American Medical Group Association, participated in a Capitol Hill briefing, 'Saving Lives, Saving Money: Modernizing Healthcare through Electronic Prescribing.' Each participant in the briefing emphasized how e-prescribing is available and being used today to save lives, along with the ability of the technology to save money for both patients and the federal government. Dr. Warner, a current user of ZixCorp's PocketScript(r) e-prescribing service, discussed how e-prescribing is easy to use and alerts him to potential harmful drug interactions as well as the availability of generics or drugs with lower co-pays that would be cheaper for his patients. He further made the point that while, as physicians in a large integrated clinic, he and his colleagues see significant value from e-prescribing, it is the doctors in smaller or rural practices that would benefit to an even greater extent from the adoption of e-prescribing.
In addition to providing a higher Medicare reimbursement rate for physicians who use e-prescribing, the E-MEDS bill calls for a one-time bonus for physicians to help address the upfront costs of implementing the technology. ZixCorp's successful payor-sponsorship go-to-market model has shown that defraying the upfront costs of technology implementation as recommended in the bill further advances adoption rates of e-prescribing by eliminating cost as a barrier to adoption. ZixCorp's high-touch payor-sponsorship model embodies a high level of support to both payors and doctors for recruiting, installation, training and reporting, which also addresses the other primary barrier to adoption as identified in a recent poll of physicians, which is the administrative hassle of implementation.
``We are very pleased to see these senators, who have been at the forefront of efforts to improve the effectiveness and efficiency of our healthcare system, identify e-prescribing as the right step to modernizing the delivery of care in this country,'' said Rick Spurr, chief executive officer for ZixCorp. ``Through our multiple payor-sponsored programs across the country, we consistently see physicians such as Dr. Warner of Lahey Clinic using our PocketScript e-prescribing service to save lives and save money. ZixCorp has long been the leader in bringing e-prescribing into the physician's office and we continue to experience particular success in introducing the technology to small practices with one or two doctors, where approximately half of the primary care providers in the U.S. practice today. We believe that having leaders from both sides of the aisle and in both chambers of Congress, as well as this Administration, all supporting and willing to take the necessary measures to encourage the widespread adoption of e-prescribing will improve the safety and lower the costs of healthcare in this country.''
The eRx Collaborative -- ZixCorp's longest-running payor-sponsored e-Prescribing program, which was formed by Blue Cross and Blue Shield of Massachusetts, Tufts Health Plan and Neighborhood Health Plan in 2003 -- publicly stated that as of June 30, 2007, approximately 50,000 electronic prescriptions were changed during the first half of 2007 by the physician due to drug safety alerts, 2.1 percent of the electronic prescriptions written. Blue Cross and Blue Shield of Massachusetts has also documented a 3.0 to 3.5 percent savings in drug spending for the health plan and a $20-$25 savings per prescription for the patient in cases where physicians use e-prescribing compared with those who were writing prescriptions with pen and paper. More recently, Aetna announced that it had experienced a five to seven percent increase in use of on-formulary and generic drugs, respectively, in its New Jersey e-Prescribing pilot with ZixCorp, which also facilitates drug-drug and drug-allergy safety checks to increase patient safety.
ZixCorp's PocketScript(r) e-prescribing service enables physicians to order prescriptions through a secure wireless mobile PDA or secure Web site and deliver them electronically to the patient's preferred pharmacy. Mobility enables PocketScript to provide clinical decision support at the point-of-care with real-time access to a drug reference guide as well as patient-level eligibility, formulary, and co-pay information to aid the prescriber in selecting the most cost-effective prescription based on the patient's benefits. The application also provides comprehensive drug-to-drug and drug-to-allergy interaction alerts based on patient-specific dispensed drug history. Through partnerships with RxHub and RelayHealth, and as a SureScripts GoldRx Certified Solution(tm), PocketScript delivers end-to-end connectivity within the healthcare system to reduce unnecessary costs, improve patient safety and convenience, and enhance practice efficiency.
About Zix Corporation
ZixCorp is the leading provider of easy-to-use-and-deploy email encryption and e-prescribing
Press Release Source: Zix Corporation
Justice Federal Credit Union Selects Zix Corporation for Email Encryption Service
Tuesday November 27, 1:30 pm ET
ZixCorp's Email Encryption Service Ensures Online Communication Privacy for Credit Union That Serves U.S. Department of Justice
DALLAS, Nov. 27, 2007 (PRIME NEWSWIRE) -- Zix Corporation (ZixCorp(r)) (NasdaqGM:ZIXI - News), the leader in email encryption and e-prescribing services, today announced that the Justice Federal Credit Union has selected ZixCorp's Email Encryption Service. The Justice Federal Credit Union is the premier provider of retail financial services to the justice and law enforcement communities.
ADVERTISEMENT
Currently, 40 percent of the credit union's members are non-local with a global presence offered through the Internet. The Justice Federal Credit Union chose ZixCorp's service for email encryption, which includes pre-configured policies that encrypt email containing sensitive information. This service helps prevent accidental transmission of confidential data.
``We serve the financial needs of the U.S. Department of Justice, their employees and their families and a major factor in our decision to find an email encryption service provider is that online privacy is absolutely critical to our Department of Justice members,'' said Rifat Ikram, Vice President of Electronic Delivery and Support Services for Justice Federal Credit Union. ``ZixCorp offered a comprehensive and painless way to protect that sensitive member communication.''
As the leading email encryption provider with over 9 million protected email recipients, ZixCorp's vast directory allows seamless encrypted email delivery to healthcare organizations, insurers, financial institutions and regulators, including the federal banking regulatory agencies. ZixCorp supports five encrypted email delivery mechanisms, including S/MIME, TLS, OpenPGP, secure portal and ``push'' delivery.
``More than 500 financial institutions have selected ZixCorp's Email Encryption Service to ensure seamless, secure email communications with their partners and customers,'' said Rick Spurr, chief executive officer of ZixCorp. ``The nation's top financial organizations, such as the Justice Federal Credit Union and the influential federal and state financial regulators, continue to join the ZixDirectory, the largest email encryption directory in the world. The ZixDirectory uniquely enables communities of interest that require frequent email interaction, such as the healthcare, government and finance verticals, to have instant and transparent communication with all of the other members of the directory. As more customers join the ZixDirectory, the value of this network increases for every member.''
About Zix Corporation
ZixCorp is the leading provider of easy-to-use-and-deploy email encryption and e-prescribing services that Connect entities with their customers and partners to Protect and Deliver sensitive information in the healthcare, finance, insurance and government industries. ZixCorp's hosted Email Encryption Service provides an easy and cost-effective way to ensure customer privacy and regulatory compliance for corporate email. Its PocketScript(r) e-prescribing service saves lives and saves money by automating the prescription process between payors, doctors and pharmacies. For more information, visit http://www.zixcorp.com.
The Zix Corporation logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4086
Contact:
Zix Corporation
Public Relations:
Farrah Corley
(214) 370-2175
publicrelations@zixcorp.com
Investor Relations:
Peter Wilensky
(214) 515-7357
invest@zixcorp.com
Zix Corporation Ranked Number 17 in Deloitte's Technology Fast 50 Program for Texas
Tuesday October 16, 1:27 pm ET
Attributes 998 Percent Revenue Growth to Its Leadership in e-Prescribing and Email Encryption
DALLAS, Oct. 16, 2007 (PRIME NEWSWIRE) -- Zix Corporation (ZixCorp(r)), (NasdaqGM:ZIXI - News), the leader in email encryption and e-prescribing services, has been named to Deloitte's prestigious Technology Fast 50 Program for Texas, a ranking of the 50 fastest growing technology, media, telecommunications, and life sciences companies in Texas by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2002-2006. This year's Texas Technology Fast 50 program is co-presented by Deloitte & Touche USA LLP, CresaPartners, Gardere Wynne Sewell LLP, HumCap, NASDAQ and America's 401(k).
ADVERTISEMENT
ZixCorp's CEO Rick Spurr credits the company's 998 percent revenue growth from 2002-2006 to industry leadership driven by innovative approaches to the market. Spurr said, ``ZixCorp maintains leadership in two high-growth markets. Our revolutionary hosted e-prescribing technology is delivering documented cost savings and safety improvements within our eight payor-sponsored programs, including four of the top five heath insurance companies in the country. Our unique Email Encryption Service features a network-based, shared directory. This ZixDirectory, with over 9 million protected email addresses growing at a rate of 65,000 per week is highly scalable and makes encryption easy-to-use and simple to manage. In addition to the top line growth being recognized here, we have improved bottom-line financial results as well. Throughout 2007, ZixCorp has continued to perform ahead of plan with respect to our net cash consumption. We remain on track to attain our goal of achieving positive cash flow in the first quarter of 2008.''
``Sustaining high revenue growth over five years is an exceptional accomplishment. We commend ZixCorp for making the commitment to technology and delivering on the promise of market longevity. We are proud to name ZixCorp to Deloitte's Technology Fast 50,'' said Skip Moore, Deloitte & Touche LLP, managing partner, Technology, Media & Telecommunications.
To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2002 and $5,000,000 in 2006, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.
Companies from the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit http://www.fast500.com.
Yahoo!My Yahoo!Mail Make Y! your home pageYahoo! SearchSearch:Sign In
New User? Sign UpFinance Home -Help
Home InvestingMarket OverviewMarket StatsStocksMutual FundsETFsBondsOptionsIndustriesCurrencyEducationNews & OpinionMarketsInvesting IdeasExpert AdviceSpecial EditionsCompany FinancesProvidersPersonal FinanceBanking & BudgetingCareer & WorkCollege & EducationFamily & HomeInsuranceLoansReal EstateRetirementTaxesHow-to GuidesGet QuotesSymbol LookupFinance Search
Press Release Source: Zix Corporation
UT Southwestern Medical Center Selects Zix Corporation for Email Encryption Service
Wednesday September 5, 11:00 am ET
ZixCorp Remains Top Choice for Email Encryption in Healthcare Industry
DALLAS, Sept. 5, 2007 (PRIME NEWSWIRE) -- Zix Corporation (ZixCorp(r)) (NasdaqGM:ZIXI - News), the leader in email encryption and e-prescribing services, today announced that UT Southwestern Medical Center at Dallas has signed a three-year contract for 5,000 users to use ZixCorp's Email Encryption Service.
ADVERTISEMENT
``ZixCorp offered a simple solution for HIPAA compliance with its Email Encryption Service,'' said Stan Waddell, Chief Information Security Officer for UT Southwestern.
As the leading email encryption provider with over 8 million protected email recipients, ZixCorp's vast directory allows seamless encrypted email delivery to healthcare organizations, insurers, financial institutions and regulators, including the federal banking regulatory agencies. ZixCorp supports five encrypted email delivery mechanisms, including S/MIME, TLS, OpenPGP, secure portal and ``push'' delivery.
``ZixCorp remains the dominant email encryption service provider within the healthcare industry, including leading regional medical centers like UT Southwestern,'' said Rick Spurr, chief executive officer of ZixCorp. ``HIPAA regulations continue to be an important topic for our customers and they want the comfort of partnering with a company that can deliver a proven, effective and easy-to-use solution for protecting email communication.''
About Zix Corporation
ZixCorp is the leading provider of easy-to-use-and-deploy email encryption and e-prescribing services that Connect entities with their customers and partners to Protect and Deliver sensitive information in the healthcare, finance, insurance and government industries. ZixCorp's hosted Email Encryption Service provides an easy and cost-effective way to ensure customer privacy and regulatory compliance for corporate email. Its PocketScript(r) e-prescribing service saves lives and saves money by automating the prescription process between payors, doctors and pharmacies. For more information, visit http://www.zixcorp.com
Detailed Quote for Advanced Mineral Technologies Inc. DL 9/3/2007 12:16 PM
AMTO Last: 0.235 Change: +0.015(+6.82%) Volume: 51.12 k Last Trade: 8/31/07
Today 5 Dy 1 Mo 3 Mo 1 Yr more
Last Price
0.235
Change $
0.015
Change %
6.82%
Tick
Bid
N/A
Bid Size
N/A
Ask
N/A
Ask Size
N/A
Open
0.22
High
0.235
Low
0.20
Prev Close
0.22
Last Trade
8/31/07
Volume
51.12 k
close52 Week Information
52 Week High
June 05,2007
Close: 0.49 52 Week Low
August 02,2007
Close: 0.13 52 Wk Hi
0.49
52 Wk Low
0.13
Market Cap
N/A
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
N/A
EPS (TTM)
N/A
PE Ratio
N/A
Exchange
OTO
News for Advanced Mineral Technologies Inc. Sector News | Topic News Sector News
Basic Materials
- Chemicals
- Energy
- Metals & Mining
Conglomerates
- Conglomerates
Consumer Goods
- Consumer Durables
- Consumer Non-Durables
- Automotive
- Food & Beverage
- Tobacco
Financial
- Banking
- Financial Services
- Insurance
- Real Estate
Healthcare
- Drugs
- Health Services
Industrial Goods
- Aerospace/Defense
- Manufacturing
- Materials & Construction
Services
- Leisure
- Media
- Retail
- Specialty Retail
- Wholesale
- Diversified Services
- Transportation
Technology
- Computer Hardware
- Computer Software & Services
- Electronics
- Telecommunications
- Internet
Utilities
- Utilities
HideMarket News
AMEX
Nasdaq
NYSE
OTCBB
Pink Sheets
Mutual Funds
Commodities
TSX
World Market News
Asia Pacific
Europe
Corporate Actions
Stock Buyback
Dividends
Earnings
Stock Splits
Insider Trading
IPO's
Business & Finance
Antitrust
Banking & Finance
Capital Gains
Mergers & Acquisitions
Economy
Consumer Price Index
Bond/Stock Update
Federal Reserve
Foreign Exchange
International Monetary Fund
Interest Rates
Hide
Tue, Aug 21, 2007
10:32 AM Advanced Mineral Technologies, Inc. Appoints New Corporate Counsel - Business Wire
Wed, Aug 08, 2007
8:32 AM Advanced Mineral Technologies, Inc. Announces Appointments of New Board Members - Business Wire
Mon, Jul 16, 2007
7:59 PM Advanced Mineral Technologies Inc. Advises Tillicum Mountain Gold Deal Completed - Market Wire
More News for AMTO More Filings for AMTO
MP check this out.
http://www.deltanu.com/dn06/solutions/pharm.htm
MP you have some more competition!
http://www.pharmacychoice.com/News/article.cfm?Article_ID=47676
CEXI and MP have some more competition.
http://www.deltanu.com/dn06/brochures/sd_app74.pdf
arloco, The only thing that we can do is check the otcbb daily list under security deletions failure to comply.
http://www.otcbb.com/asp/dailylist_detail.asp?d=06/14/2007&mkt_ctg=OTCBB
You are correct on strike 3.
Capnmike,Mark is a good person,Let's hope that he can help MP with financing a small cap like CDE-X.
Xenophon,The next failure to file on time be # 3.
Furthermore, filings for reporting periods ending before October 1,
2005 will not be considered for purposes of this paragraph (e).
* * * * *